The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Implications of GABAergic Neurotransmission in Alzheimer’s Disease
Open accessAbstract
Alzheimer's disease (AD) is characterized pathologically by the deposition of β-amyloid peptides (Aβ) and the accumulation of neurofibrillary tangles (NFTs) composed of hyper-phosphorylated tau. Regardless of the pathological hallmarks, synaptic dysfunction is widely accepted as a causal event in AD. Of the two major types of synapses in the central nervous system (CNS): glutamatergic and GABAergic, which provide excitatory and inhibitory outputs respectively, abundant data implicate an impaired glutamatergic system during disease progression. However, emerging evidence supports the notion that disrupted default neuronal network underlies impaired memory, and that alterations of GABAergic circuits, either plays a primary role or as a compensatory response to excitotoxicity, may also contribute to AD by disrupting the overall network function. The goal of this review is to provide an overview of the involvement of Aβ, tau and apolipoprotein E4 (apoE4), the major genetic risk factor in late-onset AD (LOAD), in GABAergic neurotransmission and the potential of modulating the GABAergic function as AD therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors
Farrant, M., & Nusser, Z. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1625 · Cited by 2,081 · cited 2×
“In CNS, the inhibitory action of GABA can be broadly divided into two classes: phasic inhibition and tonic inhibition (Farrant and Nusser, 2005; McQuail et al., 2015).”
BackgroundAlzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
Palop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., Yoo, J., Ho, K. O., Yu, G.-Q., Kreitzer, A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.025 · Cited by 1,653 · cited 3×
“These alterations are characterized as compensatory inhibitory mechanisms to ameliorate neuronal overexcitation and keep the normal neuronal excitation (Palop et al., 2007).”
BackgroundDistinct patterns of brain activity in young carriers of the APOE -ε4 allele
Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., Matthews, P. M., Beckmann, C. F., & Mackay, C. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811879106 · Cited by 1,613
Verret, L., Mann, E. O., Hang, G. B., Barth, A. M. I., Cobos, I., Ho, K., Devidze, N., Masliah, E., Kreitzer, A. C., Mody, I., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.046 · Cited by 1,216
Barnard, E. A., Skolnick, P., Olsen, R. W., Möhler, H., Sieghart, W., Biggio, G., Bræstrup, C., Bateson, A. N., & Langer, S. Z. (1998) · PubMed · Cited by 1,204
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037 · cited 1×
“It has been demonstrated that increasing tau phosphorylation reduces its affinity for microtubules (Iqbal et al., 2005).”
BackgroundTau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965
The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862
Biochemistry and Cell Biology of Tau Protein in Neurofibrillary Degeneration
Mandelkow, E.-M., & Mandelkow, E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006247 · Cited by 847
GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease
Jo, S., Yarishkin, O., Hwang, Y. J., Chun, Y. E., Park, M., Woo, D. H., Bae, J. Y., Kim, T., Lee, J., Chun, H., et al. (2014) · Nature Medicine · doi:10.1038/nm.3639 · Cited by 783
Tau protein pathology in neurodegenerative diseases
Spillantini, M. G., & Goedert, M. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01337-x · Cited by 683
Mattson, M. P., Cheng, B., Culwell, A. R., Esch, F. S., Lieberburg, I., & Rydel, R. E. (1993) · Neuron · doi:10.1016/0896-6273(93)90315-i · Cited by 656
Barnard, E. A., Skolnick, P., Olsen, R. W., Mohler, H., Sieghart, W., Biggio, G., Braestrup, C., Bateson, A. N., & Langer, S. Z. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01363-2 · Cited by 632
Collinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05572.2002 · Cited by 628 · cited 1×
“It’s reported that α5 subunit deficiency enhanced hippocampus-dependent memory and spatial learning ability in mice (Collinson et al., 2002; Crestani et al., 2002).”
BackgroundBormann, J. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01413-3 · Cited by 628
ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608 · cited 1×
“Sporadic or late-onset AD (LOAD) usually develops the disease later in life, representing the majority of AD cases (Kanekiyo et al., 2014).”
Self-citationOligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease
Tu, S., Okamoto, S.-I., Lipton, S. A., & Xu, H. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-48 · Cited by 576
Self-citationTrace fear conditioning involves hippocampal α 5 GABA A receptors
Crestani, F., Keist, R., Fritschy, J.-M., Benke, D., Vogt, K., Prut, L., Blüthmann, H., Möhler, H., & Rudolph, U. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142288699 · Cited by 528
Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation and memory deficits
Xu, Z., Xiao, N., Chen, Y., Huang, H., Marshall, C., Gao, J., Cai, Z., Wu, T., Hu, G., & Xiao, M. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0056-1 · Cited by 500 · cited 7×
“The released GABA could activate both GABAA and GABAB receptors at extrasynaptic area and confer inhibitory effect (Wu et al., 2014).”
BackgroundInfluentialStructure and Pathology of Tau Protein in Alzheimer Disease
Kolarova, M., García-Sierra, F., Bartos, A., Ricny, J., & Ripova, D. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/731526 · Cited by 468
A POST-MORTEM STUDY OF THE CHOLINERGIC AND GABA SYSTEMS IN SENILE DEMENTIA
ROSSOR, M. N., GARRETT, N. J., JOHNSON, A. L., MOUNTJOY, C. Q., ROTH, M., & IVERSEN, L. L. (1982) · Brain · doi:10.1093/brain/105.2.313 · Cited by 460
Kleschevnikov, A. M., Belichenko, P. V., Villar, A. J., Epstein, C. J., Malenka, R. C., & Mobley, W. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1766-04.2004 · Cited by 459
Goodman, Y., & Mattson, M. P. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1107 · Cited by 449
The ABC of GABA receptors: a brief review
Chebib, M., & Johnston, G. A. R. (1999) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.1999.03151.x · Cited by 436
Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain
Hasegawa, M., Morishima-Kawashima, M., Takio, K., Suzuki, M., Titani, K., & Ihara, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41890-x · Cited by 430
Don't worry ‘B’ happy!: a role for GABAB receptors in anxiety and depression
Cryan, J. F., & Kaupmann, K. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.11.004 · Cited by 421
Apolipoprotein e sets the stage: response to injury triggers neuropathology
Mahley, R. W., & Huang, Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.11.020 · Cited by 412
GABAB receptors and their significance in mammalian pharmacology
Bowery, N. (1989) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(89)90188-0 · Cited by 404
Which GABA A Receptor Subunits Are Necessary for Tonic Inhibition in the Hippocampus?
Glykys, J., Mann, E. O., & Mody, I. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4751-07.2008 · Cited by 370 · cited 1×
“Tonic inhibition has been demonstrated to be mainly mediated by extrasynaptic GABAA receptors containing π subunit in most brain regions, and GABAA receptors containing α5 subunit especially in hippocampus (Glykys et al., 2008).”
BackgroundProteolytic processing of Alzheimer’s β‐amyloid precursor protein
Zhang, H., Ma, Q., Zhang, Y., & Xu, H. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07519.x · Cited by 343
Self-citationWu, Z., Guo, Z., Gearing, M., & Chen, G. (2014) · Nature Communications · doi:10.1038/ncomms5159 · Cited by 306 · cited 6×
“The released GABA could activate both GABAA and GABAB receptors at extrasynaptic area and confer inhibitory effect (Wu et al., 2014).”
BackgroundInfluentialLi, G., Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Ring, K., Halabisky, B., Deng, C., Mahley, R. W., & Huang, Y. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.10.015 · Cited by 288
Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia
Kehrer, C. (2008) · Frontiers in Molecular Neuroscience · doi:10.3389/neuro.02.006.2008 · Cited by 287
Lüscher, B., & Keller, C. A. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.04.003 · Cited by 284
The γ2 subunit of GABAA receptors is required for maintenance of receptors at mature synapses
Schweizer, C. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00202-1 · Cited by 267
Loss of functional GABA A receptors in the Alzheimer diseased brain
Limon, A., Reyes-Ruiz, J. M., & Miledi, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204606109 · Cited by 264
Models of β-amyloid induced Tau-pathology: The long and “folded” road to understand the mechanism
Stancu, I.-C., Vasconcelos, B., Terwel, D., & Dewachter, I. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-51 · Cited by 256
The main source of ambient GABA responsible for tonic inhibition in the mouse hippocampus
Glykys, J., & Mody, I. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2007.134460 · Cited by 253
Tau immunotherapy for Alzheimer's disease
Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247
An Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition
Dawson, G. R., Maubach, K. A., Collinson, N., Cobain, M., Everitt, B. J., MacLeod, A. M., Choudhury, H. I., McDonald, L. M., Pillai, G., Rycroft, W., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092320 · Cited by 241
Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level
Sadleir, K. R., Eimer, W. A., Cole, S. L., & Vassar, R. (2015) · Molecular Neurodegeneration · doi:10.1186/1750-1326-10-1 · Cited by 213 · cited 2×
“…carboxyl terminal fragment (βCTF) will be further cleaved by γ-secretase within the cell membrane, releasing neurotoxic Aβ peptides and amyloid intracellular domain (AICD; Li et al., 2014; Ohki et al., 2014; Jung et al., 2015; Neumann et al., 2015; Sadleir et al., 2015; Zhang et al., 2015).”
BackgroundInfluentialTau Phosphorylation and Sevoflurane Anesthesia: An Association to Postoperative Cognitive Impairment
Le Freche, H., Brouillette, J., Fernandez-Gomez, F.-J., Patin, P., Caillierez, R., Zommer, N., Sergeant, N., Buée-Scherrer, V., Lebuffe, G., Blum, D., et al. (2012) · Anesthesiology · doi:10.1097/aln.0b013e31824be8c7 · Cited by 212
Sun, B., Halabisky, B., Zhou, Y., Palop, J. J., Yu, G., Mucke, L., & Gan, L. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.10.003 · Cited by 205
Molecular aspects of age-related cognitive decline: the role of GABA signaling
McQuail, J. A., Frazier, C. J., & Bizon, J. L. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.05.002 · Cited by 199
Axonal BACE1 dynamics and targeting in hippocampal neurons: a role for Rab11 GTPase
Buggia-Prévot, V., Fernandez, C. G., Riordan, S., Vetrivel, K. S., Roseman, J., Waters, J., Bindokas, V. P., Vassar, R., & Thinakaran, G. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-1 · Cited by 199
Regulation of human MAPT gene expression
Caillet-Boudin, M.-L., Buée, L., Sergeant, N., & Lefebvre, B. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0025-8 · Cited by 194
SGS742: the first GABAB receptor antagonist in clinical trials
Froestl, W., Gallagher, M., Jenkins, H., Madrid, A., Melcher, T., Teichman, S., Mondadori, C. G., & Pearlman, R. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.030 · Cited by 193
β-Amyloid Causes Depletion of Synaptic Vesicles Leading to Neurotransmission Failure
Parodi, J., Sepúlveda, F. J., Roa, J., Opazo, C., Inestrosa, N. C., & Aguayo, L. G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.030023 · Cited by 179
Marcade, M., Bourdin, J., Loiseau, N., Peillon, H., Rayer, A., Drouin, D., Schweighoffer, F., & Désiré, L. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05396.x · Cited by 175
Alterations in Cortical Excitation and Inhibition in Genetic Mouse Models of Huntington's Disease
Cummings, D. M., André, V. M., Uzgil, B. O., Gee, S. M., Fisher, Y. E., Cepeda, C., & Levine, M. S. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1592-09.2009 · Cited by 169
GABA as a rising gliotransmitter
Yoon, B., & Lee, C. J. (2014) · Frontiers in Neural Circuits · doi:10.3389/fncir.2014.00141 · Cited by 162
Hu, J., Liu, C.-C., Chen, X.-F., Zhang, Y.-W., Xu, H., & Bu, G. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0001-3 · Cited by 161
Self-citationSynaptotoxicity of Alzheimer Beta Amyloid Can Be Explained by Its Membrane Perforating Property
Sepúlveda, F. J., Parodí, J., Peoples, R. W., Opazo, C., & Aguayo, L. G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011820 · Cited by 160
Trafficking regulation of proteins in Alzheimer’s disease
Jiang, S., Li, Y., Zhang, X., Bu, G., Xu, H., & Zhang, Y.-W. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-6 · Cited by 158
Self-citationAlzheimer’s disease: amino acid levels and brain metabolic status
Gueli, M. C., & Taibi, G. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1289-9 · Cited by 147
Synaptic dysfunction and septin protein family members in neurodegenerative diseases
Marttinen, M., Kurkinen, K. M. A., Soininen, H. S., Haapasalo, A., & Hiltunen, M. O. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0013-z · Cited by 146
The amyloid pathology progresses in a neurotransmitter-specific manner
Bell, K. F. S., Ducatenzeiler, A., Ribeiro‐da‐Silva, A., Duff, K., Bennett, D. A., & Cuello, A. C. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.034 · Cited by 139
Altered synapses and gliotransmission in Alzheimer's disease and AD model mice
Mitew, S., Kirkcaldie, M. T. K., Dickson, T. C., & Vickers, J. C. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.010 · Cited by 138
Diminished perisomatic GABAergic terminals on cortical neurons adjacent to amyloid plaques
Garcia-Marin, V. (2009) · Frontiers in Neuroanatomy · doi:10.3389/neuro.05.028.2009 · Cited by 136
Altered synaptic function in Alzheimer's disease
Bell, K. F. S., & Cuello, A. C. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.045 · Cited by 135
EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
Vellas, B., Sol, O., J. Snyder, P., Ousset, P.-J., Haddad, R., Maurin, M., Lemarie, J.-C., Desire, L., & P. Pando, M. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256053 · Cited by 133 · cited 1×
“Etazolate (EHT-0202) has entered Phase II clinical trial for the treatment of AD, with an encouraging result on safety and patient tolerance (Vellas et al., 2011).”
BackgroundActivation of α‐secretase cleavage
Postina, R. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07459.x · Cited by 127
Dysregulation of protein trafficking in neurodegeneration
Wang, X., Huang, T., Bu, G., & Xu, H. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-31 · Cited by 125
Self-citationHelm, K. A., Haberman, R. P., Dean, S. L., Hoyt, E. C., Melcher, T., Lund, P. K., & Gallagher, M. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.01.019 · Cited by 125
Tong, L. M., Djukic, B., Arnold, C., Gillespie, A. K., Yoon, S. Y., Wang, M. M., Zhang, O., Knoferle, J., Rubenstein, J. L. R., Alvarez-Buylla, A., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0693-14.2014 · Cited by 123
Atack, J. R. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.09.001 · Cited by 123
Bareggi, S. R., Franceschi, M., Bonini, L., Zecca, L., & Smirne, S. (1982) · Archives of Neurology · doi:10.1001/archneur.1982.00510230035010 · Cited by 119
Neumann, U., Rueeger, H., Machauer, R., Veenstra, S. J., Lueoend, R. M., Tintelnot-Blomley, M., Laue, G., Beltz, K., Vogg, B., Schmid, P., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0033-8 · Cited by 113
Leung, L., Andrews-Zwilling, Y., Yoon, S. Y., Jain, S., Ring, K., Dai, J., Wang, M. M., Tong, L., Walker, D., & Huang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053569 · Cited by 109
Whittington, R. A., Bretteville, A., Dickler, M., & Planel, E. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.03.004 · Cited by 106
Tapia‐Rojas, C., Lindsay, C. B., Montecinos-Oliva, C., Arrázola, M. S., Retamales-Ortega, R., Bunout, D. C., Hirsch, S., & Inestrosa, N. C. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0057-0 · Cited by 102
Liu, D.-S., Pan, X.-D., Zhang, J., Shen, H., Collins, N. C., Cole, A. M., Koster, K. P., Ben Aissa, M., Dai, X.-M., Zhou, M., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0002-2 · Cited by 99
Apolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice
Knoferle, J., Yoon, S. Y., Walker, D., Leung, L., Gillespie, A. K., Tong, L. M., Bien-Ly, N., & Huang, Y. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.2281-14.2014 · Cited by 97
Furukawa, K., & Mattson, M. P. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00398-9 · Cited by 93
Grouselle, D., Winsky-Sommerer, R., David, J. P., Delacourte, A., Dournaud, P., & Epelbaum, J. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00698-3 · Cited by 92
Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases.
Huang, Y. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833af368 · Cited by 82
Analysis of in vivo turnover of tau in a mouse model of tauopathy
Yamada, K., Patel, T. K., Hochgräfe, K., Mahan, T. E., Jiang, H., Stewart, F. R., Mandelkow, E., & Holtzman, D. M. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0052-5 · Cited by 82
Atack, J. R., Maubach, K. A., Wafford, K. A., O'Connor, D. V., Rodrigues, A. D., Evans, D. C., Tattersall, F. D., Chambers, M. S., MacLeod, A. M., Eng, W., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157636 · Cited by 77
Lee, B. Y., Ban, J. Y., & Seong, Y. H. (2005) · Neuroscience Research · doi:10.1016/j.neures.2005.04.008 · Cited by 74
Bell, K. F. S., de Kort, G. J. L., Steggerda, S., Shigemoto, R., Ribeiro‐da‐Silva, A., & Cuello, A. C. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.09.027 · Cited by 70
Zimmer, R., Teelken, A. W., Trieling, W. B., Weber, W., Weihmayr, T., & Lauter, H. (1984) · Archives of Neurology · doi:10.1001/archneur.1984.04210080010005 · Cited by 68
Astrocytes as GABA-ergic and GABA-ceptive Cells
Yoon, B. E., Woo, J., & Lee, C. J. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0808-z · Cited by 65
Knust, H., Achermann, G., Ballard, T. M., Buettelmann, B., Gasser, R., Fischer, H., Hernandez, M., Knoflach, F., Koblet, A., Stadler, H., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.053 · Cited by 63
Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation
Nilsen, L. H., Rae, C., Ittner, L. M., Götz, J., & Sonnewald, U. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.212 · Cited by 62 · cited 2×
“In the nervous system, maintaining a proper dynamic balance between the excitatory glutamate and inhibitory GABA neurotransmitters is critical for neuronal function.”
BackgroundTau pathogenesis is promoted by Aβ1-42 but not Aβ1-40
Hu, X., Li, X., Zhao, M., Gottesdiener, A., Luo, W., & Paul, S. M. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-52 · Cited by 62
Potapenko, E. S., Biancardi, V. C., Zhou, Y., & Stern, J. E. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3936-12.2013 · Cited by 59
Siopi, E., Llufriu-Dabén, G., Cho, A. H., Vidal-Lletjós, S., Plotkine, M., Marchand‐Leroux, C., & Jafarian-Tehrani, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.009 · Cited by 59
Etazolate improves performance in a foraging and homing task in aged rats
Drott, J. T., Désiré, L., Drouin, D., Pando, M. P., & Haun, F. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.02.036 · Cited by 58
The survival of rat cerebral cortical neurons in the presence of trophic APP peptides
Yamamoto, K., Miyoshi, T., Yae, T., Kawashima, K., Araki, H., Hanada, K., Otero, D. A. C., Roch, J., & Saitoh, T. (1994) · Journal of Neurobiology · doi:10.1002/neu.480250510 · Cited by 58
Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology
Song, L., Lu, S. X., Ouyang, X., Melchor, J. P., Lee, J., Terracina, G., Wang, X., Hyde, L. A., Hess, J. F., Parker, E. M., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0011-1 · Cited by 55
Blockade of GABA(B) receptors completely reverses age-related learning impairment
LaSarge, C. L., Bañuelos, C., Mayse, J. D., & Bizon, J. L. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.08.055 · Cited by 54
Shao, H., Zhang, Y., Dong, Y., Yu, B., Xia, W., & Xie, Z. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132792 · Cited by 54
GABAB receptors function as heterodimers
Marshall, F. H., White, J. H., Main, M. J., et al. (1999) · Biochemical Society Transactions · doi:10.1042/bst0270530 · Cited by 54
González‐Burgos, G., Rotaru, D. C., Zaitsev, A. V., Povysheva, N. V., & Lewis, D. A. (2008) · Journal of Neurophysiology · doi:10.1152/jn.91161.2008 · Cited by 52
Synaptotagmins interact with APP and promote Aβ generation
Gautam, V., D’Avanzo, C., Berezovska, O., Tanzi, R. E., & Kovacs, D. M. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0028-5 · Cited by 49
Iwakiri, M., Mizukami, K., Ikonomović, M. D., Ishikawa, M., Abrahamson, E. E., DeKosky, S. T., & Asada, T. (2008) · Neuropathology · doi:10.1111/j.1440-1789.2008.00978.x · Cited by 49
Lonskaya, I., Hebron, M. L., Chen, W., Schachter, J. B., & Moussa, C. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-46 · Cited by 49
Ramos‐Miguel, A., Hercher, C., Beasley, C. L., Barr, A. M., Bayer, T. A., Falkai, P., Leurgans, S. E., Schneider, J. A., Bennett, D. A., & Honer, W. G. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0061-4 · Cited by 48
Structural biology of presenilin 1 complexes
Li, Y., Böhm, C., Dodd, R. B., Chen, F., Qamar, S., Schmitt‐Ulms, G., Fraser, P. E., & George‐Hyslop, P. S. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-59 · Cited by 47
Self-citationGolovyashkina, N., Penazzi, L., Ballatore, C., Smith, A. B., Bakota, L., & Brandt, R. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0049-0 · Cited by 44
γ-Aminobutyric Acid Type A (GABAA) Receptor Activation Modulates Tau Phosphorylation
Nykänen, N.-P., Kysenius, K., Sakha, P., Tammela, P., & Huttunen, H. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.309385 · Cited by 43
Mizukami, K., Grayson, D. R., Ikonomović, M. D., Sheffield, R., & Armstrong, D. M. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00347-1 · Cited by 37
Guzmán, E. A., Bouter, Y., Richard, B. C., Lannfelt, L., Ingelsson, M., Paetau, A. E., Verkkoniemi‐Ahola, A., Wirths, O., & Bayer, T. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-13 · Cited by 33
Getova, D. P., & Bowery, N. G. (2001) · Psychopharmacology · doi:10.1007/s002130100766 · Cited by 30
Guerrini, G., Ciciani, G., Costanzo, A., Daniele, S., Martini, C., Ghelardini, C., Mannelli, L. D. C., & Ciattini, S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.02.027 · Cited by 27
Conditional inactivation of Akt three isoforms causes tau hyperphosphorylation in the brain
Wang, L., Cheng, S., Yin, Z., Xu, C., Lu, S., Hou, J., Yu, T., Zhu, X., Zou, X., Peng, Y., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0030-y · Cited by 25
Zhang, Y., Shao, H., Dong, Y., Swain, C. A., Yu, B., Xia, W., & Xie, Z. (2014) · Translational Neurodegeneration · doi:10.1186/2047-9158-3-8 · Cited by 24
Binding of longer Aβ to transmembrane domain 1 of presenilin 1 impacts on Aβ42 generation
Ohki, Y., Shimada, N., Tominaga, A., Osawa, S., Higo, T., Yokoshima, S., Fukuyama, T., Tomita, T., & Iwatsubo, T. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-7 · Cited by 23
Guerrini, G., Ciciani, G., Cambi, G., Bruni, F., Selleri, S., Guarino, C., Melani, F., Montali, M., Martini, C., Ghelardini, C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801599a · Cited by 22
Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator
Jung, J. I., Price, A. R., Ladd, T. B., Ran, Y., Park, H.-J., Ceballos‐Diaz, C., Smithson, L. A., Hochhaus, G., Tang, Y., Akula, R., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0021-z · Cited by 21
Zhan, X., Yao, J., Liu, D., Ma, Q., & Mei, Y. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12471 · Cited by 18
Zhang, X., Yu, C., & Sisodia, S. S. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0037-4 · Cited by 17
Guerrini, G., & Ciciani, G. (2010) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-381296-4.00011-7 · Cited by 16
Cited by
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253
“[183] Li Y, SunH, Chen Z, XuH, BuG, ZhengH.”
Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
Tönnies, E., & Trushina, E. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161088 · Cited by 1,750
GABAA receptors: structure, function, pharmacology, and related disorders
Ghit, A., Assal, D., Al-Shami, A. S., & Hussein, D. E. E. (2021) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00224-0 · Cited by 405
Salehi, B., Sharifi-Rad, J., Cappellini, F., Reiner, Ž., Zorzan, D., Imran, M., Sener, B., Kilic, M., El-Shazly, M., Fahmy, N. M., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01300 · Cited by 293
Rice, H. C., de Malmazet, D., Schreurs, A., Frere, S., Van Molle, I., Volkov, A. N., Creemers, E., Vertkin, I., Nys, J., Ranaivoson, F. M., et al. (2019) · Science · doi:10.1126/science.aao4827 · Cited by 281
Metadata
- Authors
- Li, Y., Sun, H., Chen, Z., Xu, H., Bu, G., & Zheng, H.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2016-02-23
- Volume
- 8
- Pages
- 31-31
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2292595116
- Cited by
- 277
- References
- 120
- FWCI
- 15.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.